Access the full text.
Sign up today, get DeepDyve free for 14 days.
Nobuyoshi Nagamine, Takayuki Shirakawa, Yusuke Minato, Kentaro Torii, Hiroki Kobayashi, M. Imoto, Y. Sakakibara (2009)
Integrating Statistical Predictions and Experimental Verifications for Enhancing Protein-Chemical Interaction Predictions in Virtual ScreeningPLoS Computational Biology, 5
K. Steketee, Leon Timmerman, A. Made, P. Doesburg, A. Brinkmann, J. Trapman (2002)
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancerInternational Journal of Cancer, 100
M. Taplin, B. Rajeshkumar, S. Halabi, Cary Werner, B. Woda, J. Picus, W. Stadler, D. Hayes, P. Kantoff, N. Vogelzang, E. Small (2003)
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
H. Lim, K. Parker (2011)
Total synthesis of the potent androgen receptor antagonist (-)-arabilin: a strategic, biomimetic [1,7]-hydrogen shift.Journal of the American Chemical Society, 133 50
Na Liu, Wenfang Zhou, Yue‐Wei Guo, Junmei Wang, Weitao Fu, Huiyong Sun, Dan Li, Mojie Duan, Tingjun Hou (2018)
Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its CoactivatorJournal of chemical information and modeling, 58 8
F. Claessens, C. Helsen, S. Prekovic, T. Broeck, L. Spans, H. Poppel, S. Joniau (2014)
Emerging mechanisms of enzalutamide resistance in prostate cancerNature Reviews Urology, 11
Masanori Murakoshi, R. Ikeda, N. Fukui (2001)
The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia.The Journal of toxicological sciences, 26 3
J. Trapman, A. Brinkmann (1996)
The androgen receptor in prostate cancer.Pathology, research and practice, 192 7
K. Fujita, N. Nonomura (2018)
Role of Androgen Receptor in Prostate Cancer: A ReviewThe World Journal of Men's Health, 37
C. Grasso, Yi-Mi Wu, D. Robinson, Xuhong Cao, S. Dhanasekaran, Amjad Khan, M. Quist, Xiaojun Jing, R. Lonigro, J. Brenner, I. Asangani, Bushra Ateeq, S. Chun, J. Siddiqui, L. Sam, Matt Anstett, R. Mehra, John Prensner, N. Palanisamy, Gregory Ryslik, Fabio Vandin, Benjamin Raphael, L. Kunju, D. Rhodes, K. Pienta, A. Chinnaiyan, S. Tomlins (2012)
The Mutational Landscape of Lethal Castrate Resistant Prostate CancerNature, 487
G. Chlipala, Pham Tri, Pham Tri, Nguyen Hung, Aleksej Krunic, S. Shim, D. Soejarto, J. Orjala (2010)
Nhatrangins A and B, aplysiatoxin-related metabolites from the marine cyanobacterium Lyngbya majuscula from Vietnam.Journal of natural products, 73 4
Zixin Zhu, R. Becklin, Dominic Desiderio, James Dalton (2001)
Mass spectrometric characterization of the human androgen receptor ligand-binding domain expressed in Escherichia coli.Biochemistry, 40 36
M. Teo, D. Rathkopf, P. Kantoff (2019)
Treatment of Advanced Prostate Cancer.Annual review of medicine, 70
K. Kurosawa, Kosaku Takahashi, E. Tsuda (2001)
SNF4435C and D, novel immunosuppressants produced by a strain of Streptomyces spectabilis. I. Taxonomy, fermentation, isolation and biological activities.The Journal of antibiotics, 54 7
Matthew Smith, E. Antonarakis, C. Ryan, W. Berry, N. Shore, Glenn Liu, J. Alumkal, C. Higano, E. Maneval, R. Bandekar, C. Boer, Margaret Yu, D. Rathkopf (2016)
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer CohortEuropean urology, 70
Shun Saito, T. Fujimaki, W. Panbangred, Y. Igarashi, M. Imoto (2016)
Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy.Angewandte Chemie, 55 8
A. Moilanen, R. Riikonen, Riikka Oksala, Laura Ravanti, Eija Aho, G. Wohlfahrt, Pirjo Nykänen, Olli Törmäkangas, J. Palvimo, P. Kallio (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapiesScientific Reports, 5
M. Korpal, Joshua Korn, Xueliang Gao, Daniel Rakiec, D. Ruddy, Shivang Doshi, Jing Yuan, S. Kovats, Sunkyu Kim, V. Cooke, J. Monahan, F. Stegmeier, T. Roberts, W. Sellers, Wenlai Zhou, P. Zhu (2013)
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Cancer discovery, 3 9
Y. Kato, P. Scheuer (1974)
Aplysiatoxin and debromoaplysiatoxin, constituents of the marine mollusk Stylocheilus longicauda (Quoy and Gaimard, 1824).Journal of the American Chemical Society, 96 7
I. Tetko, J. Gasteiger, R. Todeschini, A. Mauri, D. Livingstone, P. Ertl, V. Palyulin, E. Radchenko, N. Zefirov, A. Makarenko, V. Tanchuk, V. Prokopenko (2005)
Virtual Computational Chemistry Laboratory – Design and DescriptionJournal of Computer-Aided Molecular Design, 19
C. Heinlein, Chawnshang Chang (2004)
Androgen receptor in prostate cancer.Endocrine reviews, 25 2
Shun Saito, T. Fujimaki, W. Panbangred, R. Sawa, Y. Igarashi, M. Imoto (2017)
Antarlides F–H, new members of the antarlide family produced by Streptomyces sp. BB47The Journal of Antibiotics, 70
Philip Watson, V. Arora, C. Sawyers (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerNature Reviews Cancer, 15
Nobuyoshi Nagamine, Y. Sakakibara (2007)
Statistical prediction of protein-chemical interactions based on chemical structure and mass spectrometry dataBioinformatics, 23 15
Chang-Zeng Wang, U. Maier, M. Keil, M. Zenk, A. Bacher, F. Rohdich, W. Eisenreich (2003)
Phenylalanine-independent biosynthesis of 1,3,5,8-tetrahydroxyxanthone. A retrobiosynthetic NMR study with root cultures of Swertia chirata.European journal of biochemistry, 270 14
Y. Igarashi, Linkai Yu, M. Ikeda, T. Oikawa, S. Kitani, T. Nihira, B. Bayanmunkh, W. Panbangred (2012)
Jomthonic acid , a modified amino acid from a soil-derived Streptomyces.Journal of natural products, 75 5
C. Tran, Samedy Ouk, N. Clegg, Yu Chen, Philip Watson, V. Arora, John Wongvipat, P. Smith-Jones, Dongwon Yoo, Andrew Kwon, Teresa Wasielewska, D. Welsbie, C. Chen, C. Higano, T. Beer, D. Hung, H. Scher, M. Jung, C. Sawyers (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 324
Wenqing Gao, J. Dalton (2007)
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).Drug discovery today, 12 5-6
Y. Ning, W. Pierce, V. Maher, Stella Karuri, Shenghui Tang, Haw-Jyh Chiu, Todd Palmby, J. Zirkelbach, Dhananjay Marathe, N. Mehrotra, Qi Liu, Debasis Ghosh, Chris Cottrell, J. Leighton, R. Sridhara, A. Ibrahim, R. Justice, R. Pazdur (2013)
Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 19
T. Kawamura, T. Fujimaki, Natsuki Hamanaka, Kentaro Torii, Hiroki Kobayashi, Yoshikazu Takahashi, M. Igarashi, N. Kinoshita, Y. Nishimura, E. Tashiro, M. Imoto (2010)
Isolation and structure elucidation of a novel androgen antagonist, arabilin, produced by Streptomyces sp. MK756-CF1The Journal of Antibiotics, 63
W. Nelson, S. Yegnasubramanian (2013)
Resistance emerges to second-generation antiandrogens in prostate cancer.Cancer discovery, 3 9
Wenqing Gao, Casey Bohl, J. Dalton (2005)
Chemistry and structural biology of androgen receptor.Chemical reviews, 105 9
Lynch Jh (1993)
Treatment of advanced prostate cancer.The Journal of family practice, 37 5
H. Borgmann, N. Lallous, Deniz Ozistanbullu, E. Beraldi, Naman Paul, Kush Dalal, L. Fazli, A. Haferkamp, P. Lejeune, A. Cherkasov, M. Gleave (2018)
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).European urology, 73 1
Casey Bohl, Wenqing Gao, Duane Miller, C. Bell, J. Dalton (2005)
Structural basis for antagonism and resistance of bicalutamide in prostate cancerProceedings of the National Academy of Sciences of the United States of America, 102
Prostate cancer (PC) is a leading cause of cancer-related death in men in Western countries. Androgen receptor (AR) signaling is a major driver of PC; therefore, androgen deprivation by medical and surgical castration is the standard treatment for patients with PC. However, over time, most patients will progress to metastatic castration-resistant PC. Enzalutamide is the only AR antagonist approved by the Food and Drug Administration for the treatment of metastatic castration-resistant PC. However, resistance to enzalutamide also develops in most patients with castration-resistant PC. Thus, there is an urgent need to develop new AR antagonists with new structures. For this purpose, we conducted both in silico and natural product screenings. From the in silico screening, we obtained T5853872 and more potent compound, STK765173. From the natural product screening, the novel compound arabilin was isolated from Streptomyces sp. MK756-CF1. Unlike STK765173, arabilin could overcome resistance to enzalutamide. Furthermore, we also extracted a novel compound, antarlide A, and its geometric isomers from Streptomyces sp. BB47. Antarlides A–F have novel 22-membered-ring macrocyclic structures, while antarlides G and H have 20-membered-ring structures. Both antarlides B and G showed potent AR antagonist activity in prostate cancer cells and could overcome resistance to enzalutamide.
The Journal of Antibiotics – Springer Journals
Published: Oct 1, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.